Inhibitory Control and Gait Adaptability in Parkinson's Disease

March 20, 2026 updated by: Yea-Ru Yang, National Yang Ming Chiao Tung University

Relationship Between Inhibitory Control and Gait Adaptability During Obstacle Crossing in People With Parkinson's Disease

People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles.

The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait adaptability in people with Parkinson's disease. Gait adaptability means the ability to adjust how a person walks in response to changes in the environment, such as stepping over obstacles.

The main questions the study aims to answer are:

  • If brain activation related to inhibitory control, measured by EEG, is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
  • If behavioral inhibitory control is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?

Participants take part in one study visit. During this visit, participants complete simple thinking tests, have their brain activity recorded using EEG, and perform walking tasks that include stepping over obstacles.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • National Yang Ming Chiao Tung University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Community

Description

Inclusion Criteria:

  • A clinical diagnosis of idiopathic Parkinson's disease;
  • Stable use of prescribed antiparkinsonian medication for at least two weeks;
  • Modified Hoehn and Yahr stage I to III;
  • Age between 18 and 80 years;
  • Ability to ambulate independently for at least 30 meters without assistive devices;
  • A Mini-Mental State Examination (MMSE) score of ≥ 24;
  • Corrected vision and hearing sufficient to effectively receive external stimuli

Exclusion Criteria:

  • The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study;
  • The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures;
  • A history of brain surgery, such as deep brain stimulation (DBS)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Event-related potential - N2
Time Frame: 1 day
Measure event-related potential through electroencephalography during the Go/No-go test
1 day
Event-related potential - P300
Time Frame: 1 day
Measure event-related potential through electroencephalography during the Go/No-go test
1 day
Stroop color and word test
Time Frame: 1 day
Record numbers of corrected color words which the subject responds within 45 sec
1 day
Step width
Time Frame: 1 day
Using the GAITRite system to measure step width
1 day
Stride length/Step length
Time Frame: 1 day
Using the GAITRite system to measure stride length and step length during obstacle crossing
1 day
Single support time
Time Frame: 1 day
Using the GAITRite system to measure single support time during obstacle crossing
1 day
Gait speed
Time Frame: 1 day
Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.
1 day
Stride length
Time Frame: 1 day
Using the GaitUp system to measure stride length during continuous obstacle-crossing walking.
1 day
Swing phase
Time Frame: 1 day
Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking.
1 day
Swing width
Time Frame: 1 day
Using the GaitUp system to measure swing width during continuous obstacle-crossing walking.
1 day
Four Square Step Test
Time Frame: 1 day
The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

August 31, 2029

Study Completion (Estimated)

August 31, 2029

Study Registration Dates

First Submitted

March 20, 2026

First Submitted That Met QC Criteria

March 20, 2026

First Posted (Actual)

March 27, 2026

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 20, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NYCU114252AF1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe